Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this observational study is to evaluate patients who are planning to administer sugammadex after rocuronium or vecuronium is used.
The main questions it aims to answer are:
Since this study is observational, only data generated under daily treatment are to be collected, and no additional tests or drug administration is conducted for the study. The patients are observed from baseline to 24 hours after the initial administration of sugammadex.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sugammadex | Drug | As this is a non-interventional study designed to collect data as part of routine clinical practice, the type and dose of neuromuscular blocking agents are all based on the clinician's judgment. |
| Measure | Description | Time Frame |
|---|---|---|
| Re-administration rate of sugammadex | The number and ratio of patients re-administered with sugammadex within 24 hours of the initial administration of sugammadex are evaluated. | baseline~24 hours after administration |
| Measure | Description | Time Frame |
|---|---|---|
| Prescription pattern of sugammadex | The ratio of patients is presented for each administered time and dose. | baseline~24 hours after administration |
| Incidence rate of postoperative residual curarization (PORC)(TOFr<0.9) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients who are planning to undergo surgery using rocuronium or vecuronium for the neuromuscular blockade and planned to receive sugammadex for the antagonist.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Choon-Hak Lim, MD | Department of Anesthesiology and Pain Medicine, Korea University Medical Center, Seoul, Korea. | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Korea University Anam Hospital | Seoul | Seongbuk-gu | 02841 | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011183 | Postoperative Complications |
| ID | Term |
|---|---|
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077122 | Sugammadex |
| ID | Term |
|---|---|
| D047408 | gamma-Cyclodextrins |
| D003505 | Cyclodextrins |
| D047028 | Macrocyclic Compounds |
| D011083 | Polycyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
The TOFr (train-of-four ratio) is measured at 3 and 30 minutes after administration of sugammadex. The number and ratio of patients with a TOFr <0.9 are defined as PORC(TOFr<0.9). The TOFr is expressed as a decimal from 0.0 up to 1.0.
| at 3 and 30 minutes after administration of sugammadex |
| Incidence rate of postoperative residual curarization (PORC)(TOFr<1.0) | The TOFr (train-of-four ratio) is measured at 3 and 30 minutes after administration of sugammadex. The number and ratio of patients with a TOFr <1.0 are defined as PORC(TOFr<1.0). The TOFr is expressed as a decimal from 0.0 up to 1.0. | at 3 and 30 minutes after administration of sugammadex |
| Analysis of clinical factors affecting sugammadex re-administration | The number and ratio of patients who had these clinical factors are evaluated. | baseline~24 hours after administration |
| Incidence rate of respiratory complications related to postoperative residual muscle relaxation after surgery | The number and ratio of patients who had respiratory complications related to postoperative residual muscle relaxation after surgery are evaluated. | time from the first administration of sugammadex ~ 24 hours after administration |
| TOFr before sugammadex administration | The TOFr (train-of-four ratio) is measured before each administration of sugammadex. The TOFr is expressed as a decimal from 0.0 up to 1.0. | baseline~24 hours after administration |
| TOFr before extubation | The TOFr (train-of-four ratio) is measured before extubation. The TOFr is expressed as a decimal from 0.0 up to 1.0. | baseline~24 hours after administration |
| Time to extubation | The time from the first administration of sugammadex or the last administration of NMBA to the time of extubation is measured in minutes. | baseline~24 hours after administration |
| Time surpassed from the expected dismissal time from the recovery room | The time of dismissal from the recovery room is recorded for each patient. | baseline~24 hours after administration |
| Ratio of unplanned transfer to the intensive care unit(excluding lung surgery and heart surgery) | The number and ratio of patients who was moved from the recovery room to the intensive care unit unplanned. | time from the first administration of sugammadex ~ 24 hours after administration |
| Incidence rate of PONV(postoperative nausea and vomiting) | The number and ratio of patients who experiences PONV(postoperative nausea and vomiting). | time from the first administration of sugammadex ~ 24 hours after administration |
| Incidence rate of adverse drug reaction | The number and ratio of patients who experiences adverse drug reactions in which their relationship to sugammadex cannot be ruled out. | time from the first administration of sugammadex ~ 24 hours after administration |
| Incidence rate of serious adverse drug reaction | The number and ratio of patients who experiences serious adverse drug reactions in which their relationship to sugammadex cannot be ruled out. | time from the first administration of sugammadex ~ 24 hours after administration |
| D003912 |
| Dextrins |
| D013213 | Starch |
| D005936 | Glucans |
| D011134 | Polysaccharides |
| D002241 | Carbohydrates |